PT - JOURNAL ARTICLE AU - Miyamoto, Sho AU - Arashiro, Takeshi AU - Adachi, Yu AU - Moriyama, Saya AU - Kinoshita, Hitomi AU - Kanno, Takayuki AU - Saito, Shinji AU - Katano, Harutaka AU - Iida, Shun AU - Ainai, Akira AU - Kotaki, Ryutaro AU - Yamada, Souichi AU - Kuroda, Yudai AU - Yamamoto, Tsukasa AU - Ishijima, Keita AU - Park, Eun-Sil AU - Inoue, Yusuke AU - Kaku, Yoshihiro AU - Tobiume, Minoru AU - Iwata-Yoshikawa, Naoko AU - Shiwa-Sudo, Nozomi AU - Tokunaga, Kenzo AU - Ozono, Seiya AU - Hemmi, Takuya AU - Ueno, Akira AU - Kishida, Noriko AU - Watanabe, Shinji AU - Nojima, Kiyoko AU - Seki, Yohei AU - Mizukami, Takuo AU - Hasegawa, Hideki AU - Ebihara, Hideki AU - Maeda, Ken AU - Fukushi, Shuetsu AU - Takahashi, Yoshimasa AU - Suzuki, Tadaki TI - Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants AID - 10.1101/2021.12.28.21268481 DP - 2022 Jan 01 TA - medRxiv PG - 2021.12.28.21268481 4099 - http://medrxiv.org/content/early/2022/01/01/2021.12.28.21268481.short 4100 - http://medrxiv.org/content/early/2022/01/01/2021.12.28.21268481.full AB - Background The immune profile against SARS-CoV-2 has dramatically diversified due to a complex combination of exposure to vaccines and infection by various lineages/variants, likely generating a heterogeneity in protective immunity in a given population. To further complicate this, the Omicron variant, with numerous spike mutations, has emerged. These circumstances have created the need to assess the potential of immune evasion by the Omicron in individuals with various immune histories.Methods The neutralization susceptibility of the variants including the Omicron and their ancestor was comparably assessed using a panel of plasma/serum derived from individuals with divergent immune histories. Blood samples were collected from either mRNA vaccinees or from those who suffered from breakthrough infections by the Alpha/Delta with multiple time intervals following vaccination.Findings The Omicron was highly resistant to neutralization in fully vaccinated individuals without a history of breakthrough infections. In contrast, robust cross-neutralization against the Omicron were induced in vaccinees that experienced breakthrough infections. The time interval between vaccination and infection, rather than the variant types of infection, was significantly correlated with the magnitude and potency of Omicron-neutralizing antibodies.Conclusions Immune histories with breakthrough infections can overcome the resistance to infection by the Omicron, with the vaccination-infection interval being the key determinant of the magnitude and breadth of neutralization. The diverse exposure history in each individual warrants a tailored and cautious approach to understanding population immunity against the Omicron and future variants.Funding This study was supported by grants from the Japan Agency for Medical Research and Development (AMED).Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the Japan Agency for Medical Research and Development (AMED) (Grant Numbers by JP21fk0108104, JP20fk0108534, and JP21fk0108615).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The medical research ethics committee of the National Institute of Infectious Diseases (NIID) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.